ProCE Banner Activity

My Take on the Recent Approval of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma

Clinical Thought

How will you incorporate belantamab mafodotin into your clinical practice for patients with relapsed/refractory multiple myeloma? Here are my thoughts.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: August 25, 2020

Expiration: August 24, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline